Brief: Meiji Holdings: Subsidiary Meiji Seika Pharma In Talks With Arcturus Therapeutics Of The Us Regarding Manufacturing And Marketing Of Replicon Vaccine In Japan To Be Used For Covid Including Omicron Variant
25/08/2022 07:07
Aug 25 (Reuters) - Meiji Holdings Co Ltd 2269.T :
* MEIJI HOLDINGS: SUBSIDIARY MEIJI SEIKA PHARMA IN TALKS
WITH
ARCTURUS THERAPEUTICS OF THE US REGARDING MANUFACTURING AND
MARKETING OF REPLICON VACCINE IN JAPAN TO BE USED FOR COVID
INCLUDING OMICRON VARIANT
Further company coverage: 2269.T
(Reporting by Tokyo Newsroom)
((+81345201189;))